Key Highlights

  • ORIC shares traded up 9.20% to $13.89, versus a prior close of $12.72.
  • Enozertinib data in first-line EGFR atypical NSCLC will be presented at ESMO.
  • A company conference call and webcast is set for Oct. 23.
  • JPMorgan raised its target to $26 from $23, and Wells Fargo kept Buy with a $25 target.
  • Cash of $388 million funds operations into the second half of 2028.

Investors Position Before ESMO Enozertinib Data

ORIC Pharmaceuticals (NASDAQ:ORIC) shares traded up 9.20% to $13.89 as investors positioned for enozertinib data at the ESMO Congress in Madrid from Oct. 23 to 27. Abstracts were published this week, and the company will host a call and webcast on Oct. 23 to review the Phase 1b first-line results.

Enozertinib is a brain-penetrant EGFR inhibitor being studied in non-small cell lung cancer with EGFR atypical mutations. A poster on the data is scheduled for Oct. 26.

Rinzimetostat Phase 3 Adds a Second Prostate Cancer Story

ORIC will also present a trial-in-progress poster on rinzimetostat, an allosteric PRC2 inhibitor in the Phase 3 Himalayas-1 study in metastatic prostate cancer with Bayer's darolutamide, along with a preclinical poster on the drug's mechanism.

Analyst Support Is Strong, but Targets Sit Well Above the Price

JPMorgan raised its target to $26 from $23, and Wells Fargo reiterated Buy with a $25 target. The consensus target is about $23, well above the current price. The stock outpaced the sector and is near its 52-week high of $14.68, against a low of $7.23.

ORIC has about $388 million in cash to fund operations into the second half of 2028, a market capitalization of about $1.44 billion and earnings per share at a loss of $1.35.

ESMO Data and an Early 2027 Phase 3 Plan Set the Agenda

A Phase 3 study for enozertinib is planned for early 2027. Investors will weigh the ESMO data and the Oct. 23 call for evidence that supports that plan. As a company with no product revenue, ORIC's value depends on clinical data and access to capital.